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Therapeutic options for patients with advanced-stage hepatocellular carcinoma (HCC) are very limited. The only 
approved first-line treatment is the multi-tyrosine kinase inhibitor sorafenib, which shows low response rates and 
severe side effects. In particular, the compensatory activation of growth factor receptors leads to chemoresistance and 
limits the clinical impact of sorafenib. However, combination approaches to improve sorafenib have failed. Here we 
investigate the inhibition of cyclin-dependent kinase 5 (Cdk5) as a promising combination strategy to improve 
sorafenib response in HCC. Combination of sorafenib with Cdk5 inhibition (genetic knockdown by short hairpin 
RNA or CRISPR/Cas9 and pharmacologic inhibition) synergistically impaired HCC progression in vitro and in 
vivo by inhibiting both tumor cell proliferation and migration. Importantly, these effects were mediated by a mecha-
nism for Cdk5: A liquid chromatography–tandem mass spectrometry–based proteomic approach revealed that Cdk5 
inhibition interferes with intracellular trafficking, a process crucial for cellular homeostasis and growth factor recep-
tor signaling. Cdk5 inhibition resulted in an accumulation of enlarged vesicles and respective cargos in the perinu-
clear region, considerably impairing the extent and quality of growth factor receptor signaling. Thereby, Cdk5 
inhibition offers a comprehensive approach to globally disturb growth factor receptor signaling that is superior to 
specific inhibition of individual growth factor receptors. Conclusion: Cdk5 inhibition represents an effective approach 
to improve sorafenib response and to prevent sorafenib treatment escape in HCC. Notably, Cdk5 is an addressable 
target frequently overexpressed in HCC, and with Dinaciclib, a clinically tested Cdk5 inhibitor is readily available. 
Thus, our study provides evidence for clinically evaluating the combination of sorafenib and Dinaciclib to improve 
the therapeutic situation for patients with advanced-stage HCC. (Hepatology 2019;69:376-393).
Patients diagnosed with hepatocellular carci-noma (HCC) face a very poor prognosis.(1) Treatment options are limited, and cura-
tive treatment strategies like surgical liver resec-
tion or liver transplantation are only suitable for 
patients with early-stage HCC.(2) For patients with 
advanced-stage HCC, there are only few systemic 
therapies available, and the multi-tyrosine kinase 
inhibitor sorafenib is the only approved first-line 
therapy.
The small molecule sorafenib acts through the 
inhibition of various tyrosine kinases, such as 
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vascular endothelial growth factor receptor, plate-
let-derived growth factor receptor, and Raf fam-
ily kinases.(3) Unfortunately, only a small group of 
patients responds to sorafenib treatment and the 
survival benefit is limited to about 3 months, while 
severe side effects often lead to dose reduction or 
discontinuation of treatment.(4) In particular, the 
compensatory activation of survival pathways like 
growth factor receptor signaling upon sorafenib 
treatment is responsible for chemoresistance and 
limited treatment efficacy.(5) However, combinations 
of sorafenib with various chemotherapeutics to avoid 
chemoresistance have been unsuccessful so far.(6) In 
the last decade, strong efforts were put into improv-
ing the therapeutic situation of advanced-stage 
HCC patients, which led to significant advances 
in the recent past. For example, Regorafenib has 
recently been approved as second-line treatment 
for patients with HCC progressing under sorafenib 
treatment.(7) Further, Lenvatinib, as first-line treat-
ment, and Cabozantinib, as second-line treatment, 
have shown promising results in clinical phase 3 
trials and are expected to be approved for HCC 
treatment.(8,9) However, sorafenib is still the only 
approved first-line treatment for patients with 
advanced-stage HCC. Therefore, the search for new 
therapeutic approaches is urgent.
We recently elucidated an important role of 
cyclin-dependent kinase 5 (Cdk5) in HCC.(10) 
Cdk5 is an atypical member of the cyclin-dependent 
kinase family, which has been extensively studied in 
the central nervous system, where it is involved in 
the development of various neurodegenerative dis-
eases like Alzheimer’s and Parkinson’s disease.(11) In 
recent years, information on the extraneuronal role 
of Cdk5 has been expanded and the involvement 
of Cdk5 in various types of cancer has been char-
acterized (reviewed in(12)). We showed that Cdk5 is 
overexpressed in human HCC and promotes cancer 
progression by regulating DNA damage response. 
Consistently, inhibition of Cdk5 sensitized HCC cells 
to DNA damaging agents, which are only accepted 
for patients with intermediate-stage HCC.
Here, we propose the inhibition of Cdk5 as an 
effective strategy to improve sorafenib therapy. We 
uncovered a mode of action for Cdk5 in HCC. By 
targeting the cellular trafficking equilibrium, rather 
than interfering with individual growth factor recep-
tors, Cdk5 inhibition offers a global approach to pre-
vent the compensatory activation of growth factor 
receptors and thus increases the therapeutic efficacy 
of sorafenib.
In summary, our study offers a reasonable preclini-
cal basis for the combination of sorafenib with Cdk5 
inhibitors for treatment of patients with advanced-
stage HCC.
Materials and Methods
IN VIVO eXperIMeNtS
All experiments were performed according to 
German legislation of animal protection and were 
approved by the local government authorities. As 
HUH7 cells are derived from human tumors, severe 
combined immunodeficient (SCID) mice had to 
be used to avoid tumor cell rejection. RIL175 cells 
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originate from C57BL/6 mice, so the corresponding 
mice could be used. The albino phenotype was neces-
sary for in vivo bioluminescence measurements.
ectopic tumor Model
Twenty female SCID “CB17/lcr-PrkdcSCID/
lcrlcocrl” mice, 6 weeks old, purchased from Charles 
River, were used. We subcutaneously injected 3.3 × 
106 nontargeting (nt) or Cdk5 short hairpin RNA 
(shRNA) HUH7 cells into the flank of female 
SCID mice. Sorafenib was injected intraperitone-
ally (100 µL, solvent: 5% DMSO, 10% Solutol, 85% 
phosphate-buffered saline [PBS]). Treatment with 
sorafenib was started 10 days after implantation with 
10 mg/kg sorafenib injected daily for 7 days. Tumor 
volume was measured every second day with a caliper 
and calculated with the formula π/6 × L × W × H. 
Eighteen days after the implantation, all mice were 
sacrificed through cervical dislocation. For the statisti-
cal evaluation of tumor growth, an exponential growth 
model was used to model tumor volume, where the 
tumor volume at a given time t (N(t)) is a function of 
the starting volume N(0), the time of growth t and of 
the growth rate α: N(t) = N(0) × exp(α · t). Modelling 
was performed using nonlinear mixed effects model-
ling with the software NONMEM 7.3.
dissemination assay: dinaciclib
Twenty female C57BL/6 albino “C57BL/6Brd 
CrHsd-Tyrc” mice, 6 weeks old, purchased from 
Envigo, were used. The mice were pretreated 
 intraperitoneally with 10 mg/kg Dinaciclib or solvent 
(5% DMSO, 10% Solutol, 85% PBS) three times (48, 
24, and 0.5 hours) before cell injection. We intrave-
nously injected 2 × 105 Ril175-luc cells into the tail 
vein. Mice were imaged on day 3 after receiving an 
intraperitoneal injection of 6 mg/mL luciferin/mouse. 
Prior to imaging, mice were put under anesthesia 
with 3% isoflurane in oxygen. Mice were imaged in 
ventrodorsal position. During luminescence measure-
ment using the IVIS Lumina system (PerkinElmer), 
mice were kept under narcosis with 2% isoflurane in 
oxygen, and hypothermia was prevented by a heating 
plate (37°C). The tumor signal per defined region 
of interest was calculated with the Living Image 4.4 
software (Caliper Life Sciences) as photons/second/
cm2 (total flux/area).
dissemination assay: Cdk5 Ko
Twenty female C57BL/6 albino “C57BL/ 
6BrdCrHsd-Tyrc” mice, 6 weeks old, purchased from 
Envigo, were used. We intravenously injected 2 × 105 
Ril175-luc cells (either wild-type or Cdk5 knockout 
[KO]) into the tail vein. Luminescence measurement 
was performed as described in Dissemination Assay: 
Dinaciclib.
IMMUNoStaININg
Colocalization
For immunostaining experiments, nt and Cdk5 
shRNA HUH7 cells were seeded into 8–well ibi-
Treat µ-slides (Ibidi GmbH, Munich, Germany). 
Cells were washed with ice-cold PBS+ Ca2+/Mg2+ 
once and fixed in 4% paraformaldehyde for 15 min-
utes, before being washed with PBS once. In order 
to permeabilize the cells, 0.2% Triton X-100 (Merck, 
Darmstadt, Germany) was applied for 20 minutes. 
Unspecific antibody binding sites were blocked by 
incubation with 0.2 % bovine serum albumin (BSA; 
Sigma Aldrich, Taufkirchen, Germany) in PBS for 
20 minutes. Afterward, cells were incubated with 
primary antibodies against epidermal growth factor 
receptor (EGFR; 1:150, Cell Signaling Technologies, 
4267) and early endosome antigen 1 (1:150, Santa 
Cruz Biotechnology, sc-6415) for 1 hour. Thereafter, 
cells were washed with PBS and incubated with Alexa 
Fluor 488 and 546 secondary antibodies (1:400, 
Molecular Probes/Invitrogen, A – 11008, A – 11056) 
together with 5 µg/µL Hoechst 33342 (1:200, Sigma 
Aldrich, Taufkirchen, Germany) in PBS containing 
0.2% BSA for 30 minutes. Each well was then covered 
with FluorSave reagent mounting medium (Merck, 
Darmstadt, Germany) and glass coverslips. Images 
were taken with a Leica SP8 confocal laser scanning 
microscope (Leica Microsystems, Wetzlar, Germany).
egFr Surface localization
For the analysis of EGFR localized exclusively 
at the cell surface, nt and Cdk5 shRNA HUH7 or 
Hep3B cells were seeded into 8-well ibiTreat µ-slides 
and treated with sorafenib (0.5 µM, 5 µM, 24 hours). 
Afterward, incubation cells were immediately put on 
ice and incubated with a primary antibody target-
ing the extracellular domain of the EGFR (1:150, 
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Calbiochem, GR01) for 1 hour at 4°C. After anti-
body staining, cells were washed twice with ice-cold 
PBS and fixed in 4% paraformaldehyde for 8 minutes 
on ice. Thereafter, cells were washed with PBS and 
incubated with Alexa Fluor 488 secondary antibody 
together with 5 µg/mL Hoechst 33342 in PBS con-
taining 0.2% BSA for 30 minutes. Each well was then 
covered with FluorSave reagent mounting medium 
and glass coverslips. Images were taken with a Leica 
SP8 confocal laser scanning microscope.
egF Uptake and elimination
nt and Cdk5 shRNA cells were seeded in 8-well 
ibiTreat µ-slides and treated with 100 ng/mL EGF 
Rhodamine (Thermo Fisher Scientific, E3481) for 
various time points. In the chase (elimination) exper-
iments, EGF Rhodamine was removed after 30 min-
utes of incubation, and cells were washed twice with 
prewarmed PBS and incubated for various time points 
in medium without FCS. After incubation and chase, 
cells are immediately put on ice, washed twice with 
ice-cold PBS, and incubated with acid wash solution 
(acetic acid 0.2 M, NaCl 0.5 M, pH 2.0) for 5 minutes 
to remove excess EGF. Cells are then washed with 
PBS twice and fixed in 4% paraformaldehyde. Each 
well was then covered with FluorSave reagent mount-
ing medium and glass coverslips. Images were taken 
with a Leica SP8 confocal laser scanning microscope.
live Cell Imaging/time lapse 
Microscopy
nt and Cdk5 shRNA HUH7 or Hep3B cells were 
seeded in 8-well ibiTreat µ-slides at a density of 5 × 
104 and transfected with either EGFR-green fluo-
rescent protein (GFP; a gift from Alexander Sorkin, 
Addgene plasmid #32751), pLenti-MetGFP (a gift 
from David Rimm, Addgene plasmid #37560), or 
Alpha 5 integrin-GFP (a gift from Rick Horwitz, 
Addgene plasmid #15238) using DharmaFECT 
1 transfection reagent (ThermoFisher Scientific, 
Waltham, MA). For the experiments on autophagic 
flux, the Premo Autophagy Tandem Sensor RFP-
GFP-LC3B Kit with the RFP-GFP-LC3 plasmid 
(ThermoFisher Scientific, Waltham, MA) was used 
according to the manufacturer’s protocol. The use of 
this RFP-GFP-LC3 plasmid enables a detailed anal-
ysis of the autophagic flux, as GFP is quenched at the 
transition from autophagosome to lysosome, resulting 
in a shift from green and red fluorescent vesicles to 
only red fluorescent vesicles.
Cells were imaged using a Leica SP8 confocal laser 
scanning microscope. Frames were taken every 0.75 
seconds for a total of 10 minutes. For the quantifi-
cation of vesicle size, two types of objects have been 
considered: small vesicles (present in both conditions) 
and “ring shaped” vesicles (present only in Cdk5 
shRNA HUH7 cells). The ParticleSizer Plugin of 
Fiji after background removal is used to recognize the 
small vesicles, and a Circular Hough Transform–based 
algorithm implemented by the Matlab imfindcircles 
function is used to recognize the “ring shaped” ves-
icles only in the Cdk5 knockdown condition after 
background removal. If the two kinds of vesicles 
are overlapping, only the donut-shaped ones will be 
considered.
Results
Cdk5 INHIBItIoN IMproVeS 
SoraFeNIB reSpoNSe IN HCC  
IN VITRO aNd IN VIVO
To test the functional effects of the combina-
tion of sorafenib and Cdk5 inhibition, we used the 
human HCC cell lines HUH7 and Hep3B, as well 
as RIL175, an HCC cell line derived from C57BL/6 
mice. We silenced Cdk5 by shRNA, CRISPR/Cas9 
knockout, or interfered with its kinase activity by 
using two well-established pharmacologic inhib-
itors, Roscovitine and Dinaciclib, and the exper-
imental Cdk5 inhibitor LGR1407 (Supporting 
Fig. S1A-C). Cdk5 knockdown and inhibition 
synergistically enhanced the sorafenib-mediated 
blockade of HCC cell proliferation and clonogenic 
survival (Fig. 1A-D and Supporting Fig. S1D). For 
the evaluation of synergism, two separate models, 
namely Combination Subthresholding and Bliss 
Independence, were used. Both synergy models 
revealed a significant effect of the combination of 
sorafenib and Cdk5 inhibition compared with single 
treatments (respective Bliss values are indicated in 
Fig. 1A-D). Importantly, similar and striking syner-
gistic effects were observed when the combination of 
Cdk5 inhibition and sorafenib was administered in 
a murine HCC xenograft model (Fig. 1E,F). Tumor 
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volume was observed over time and subjected to a 
nonlinear mixed effects modelling technique, which 
revealed a synergistic effect of the combination of 
sorafenib and Cdk5 inhibition resulting in a signifi-
cantly reduced tumor growth rate.
In addition to the antiproliferative effect, sorafenib 
and Cdk5 inhibition reduced HCC cell migration 
(Fig. 2A). Notably and somewhat surprisingly, low-
dose sorafenib treatment increased HCC migration 
and invasion (Fig. 2B-F) in a proliferation-indepen-
dent fashion (Supporting Fig. S1E). Genetic knock-
down and pharmacological inhibition of Cdk5, 
importantly, not only reduced the overall motility but 
also prevented the sorafenib-induced increase of HCC 
cell migration and invasion (Fig. 2B-F). Furthermore, 
Cdk5 knockout by CRISPR/Cas9 and pharmacologic 
inhibition impaired HCC cell dissemination in vivo 
(Fig. 2G,H).
Cdk5 INHIBItIoN SeNSItIZeS to 
SoraFeNIB By preVeNtINg tHe 
CoMpeNSatory aCtIVatIoN oF 
groWtH FaCtor reCeptorS
DNA damage is involved in the pathogenesis of 
liver disease and HCC progression.(13) We have pre-
viously shown that Cdk5 inhibition sensitized HCC 
cells to the treatment with DNA damage-inducing 
agents by regulating DNA repair mechanisms, ulti-
mately resulting in apoptosis.(10) However, DNA 
damage response and apoptosis were not modulated 
by the combination of sorafenib and Cdk5 inhibition 
(Supporting Fig. S2A-C).
To obtain clues as to mechanisms through which 
Cdk5 inhibition sensitizes to sorafenib treatment, 
we took advantage of an LC-MS/MS-based pro-
teomic approach and identified proteins whose levels 
were differentially controlled by Cdk5 knockdown 
alone and in combination with sorafenib (Fig. 3A,B; 
Supporting Fig. S3A,B and S4A-C). The identified 
proteins were biologically related, as shown by a 
protein–protein interaction network analysis (Fig. 
3C; Supporting Fig. S3C). In addition, functional 
enrichment analysis revealed a modulation of pro-
teins associated with cellular metabolism (Fig. 3C). 
Moreover, interestingly, we observed an accumula-
tion of proteins regulated by intracellular traffick-
ing including proteins associated with autophagy 
like p62/Sequestosome1 and proteins trafficked via 
endocytosis like integrins or the EGFR (Fig. 3C,D). 
In order to elucidate the mode of action of Cdk5 
inhibition to sensitize for sorafenib, we set out to 
test the importance of the identified pathways.
First, we analyzed HCC metabolism. Sorafenib 
reduced glycolysis and oxidative phosphorylation; 
however, Cdk5 inhibition had no additional effect 
(Supporting Fig. S5). Thus, modulation of cell metab-
olism is unlikely to mediate the sensitizing effect of 
Cdk5 inhibition and sorafenib.
Second, an accumulation of p62/Sequestosome1, 
a marker for proteins designated for autophagy, 
provided evidence that the autophagic flux was 
perturbed by Cdk5 inhibition (Fig. 4A,B). The rel-
evance of this alteration was corroborated by an 
increased LC3-II/I ratio upon Cdk5 knockdown 
(Fig. 4A,C). To assess whether Cdk5 knockdown 
induced a degradation block or increased autoph-
agy, an artificial degradation block was applied by 
inhibiting vesicle fusion using Concanamycin A. 
Concanamycin A increased the LC3-II/I ratio in 
FIg. 1. Combination of Cdk5 inhibition and sorafenib impairs HCC growth in vitro and in vivo. (A) Proliferation of nt and Cdk5 
shRNA HUH7 cells after treatment with sorafenib (5 µM) is shown. Corresponding doubling time is shown. One-way analysis of 
variance (ANOVA), Tukey *P < 0.05, n = 3. Bliss Value = 1.98. (B) Proliferation of nt and Cdk5 shRNA Hep3B cells treated with 
sorafenib (5 µM) is shown. Corresponding doubling time is shown. One-way ANOVA, Tukey **P < 0.01, n = 3. Bliss Value = 2.27. 
(C) Proliferation of HUH7 cells treated with sorafenib (5 µM), dinaciclib (10 nM), or a combination of both is shown. Corresponding 
doubling time is shown. One-way ANOVA, Tukey *P < 0.05, n = 3. Bliss Value = 1.75. (D) Proliferation of HUH7 cells treated with 
sorafenib (5 µM), LGR1407 (7.5 µM), or a combination of both is shown. Corresponding doubling time is shown. One-way ANOVA, 
Tukey *P < 0.05, n = 3. Bliss Value = 1.46. (A-D) Upper panel: one representative graph (out of three independent experiments) showing 
cell index over time. Lower panel: Bar diagram showing the statistical analysis of cell index (upper panel) expressed as doubling time. 
(E) Tumors of nt and Cdk5 shRNA HUH7 cells grown in SCID mice that were treated with either sorafenib or solvent are shown 
(n = 6). Tumor volume over the treatment period of 18 days is shown. The table shows the statistical evaluation of growth rates that 
were determined from tumor volumes by applying an exponential tumor growth model, which showed a significantly reduced tumor 
growth rate by combining Cdk5 inhibition with sorafenib (*P < 0.05). (F) Immunostaining of respective tumors from E for Ki67 (red) 
and hematoxylin (nuclei, blue) is shown. The bar graph indicates proliferating cells evaluated by counting Ki67-positive cells. One-way 
ANOVA, Tukey ****P < 0.0001, n = 6.
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nt shRNA cells but had no effect in Cdk5 shRNA 
cells, pointing to a degradation block caused by 
Cdk5 knockdown (Fig. 4D-F). The disturbance in 
autophagic flux was further corroborated by using 
an RFP-GFP-LC3 sensor to visualize the progres-
sion from autophagosomes to autolysosomes. In 
fact, we observed strongly enlarged autophagosomes 
in Cdk5 shRNA HUH7 compared with nt shRNA 
HUH7 (Fig. 4G). However, sorafenib affected nei-
ther p62 levels nor LC3 conversion (Fig. 4A-C). 
Thus, we concluded that inhibition of Cdk5 signifi-
cantly disturbed autophagic flux, but this effect is 
not specifically responsible for the sensitizing effect 
of Cdk5 inhibition and sorafenib.
Thirdly, interestingly, the proteomic screen demon-
strated that Cdk5 inhibition induced an upregulation 
of proteins dependent on intracellular trafficking (Fig. 
3D). This suggested that intracellular trafficking was 
interrupted by Cdk5 inhibition, resulting in accumu-
lation of respective cargos. Among the cargos accu-
mulated by Cdk5 inhibition, especially the EGFR 
attracted our attention, as the upregulation of growth 
factor receptors usually correlates with a more aggres-
sive tumor progression.(14) Therefore, in order to 
elucidate this apparent discrepancy between the ele-
vation of the EGFR on the one hand, and inhibition 
of growth on the other hand, we used the EGFR as 
a good example to investigate the effects of sorafenib 
and Cdk5 inhibition on the compensatory activation 
of growth factor receptors.
Compensatory activation of growth factor sig-
naling including EGF-, insulin-like growth fac-
tor-, fibroblast growth factor-, or hepatocyte growth 
factor signaling was described as a mechanism of 
HCC to adapt to sorafenib treatment.(15-17) In line, 
our results corroborated compensatory activation 
of growth factor receptor signaling by sorafenib. 
Whereas the Ras/Raf/MEK/ERK pathway was 
impaired as shown by decreased ERK1/2 phos-
phorylation, phosphorylation of EGFR itself and 
its downstream target AKT was enhanced upon 
sorafenib (Fig. 5A,B and Supporting Fig. S6A-C). 
Moreover, sorafenib treatment increased EGFR at 
the cell surface of nt shRNA HUH7 and Hep3B 
cells, likely accounting for the increased immediate 
response of EGFR to its ligand (Fig. 5C). Of note, 
Cdk5 inhibition prevented the compensatory acti-
vation of growth factor receptor signaling. In Cdk5 
knockdown cells, AKT and EGFR phosphorylation 
were no longer induced upon sorafenib treatment 
(Fig. 5A,B and Supporting Fig. S6A-C). In addi-
tion, in Cdk5 knockdown cells, EGFR surface levels 
remained unaffected by sorafenib (Fig. 5C).
To more firmly establish the interference with 
growth factor receptor activation as a therapeutically 
relevant process that mediates the sensitizing effect of 
Cdk5 inhibition, we analyzed the effects of sorafenib 
in combination with the EGFR inhibitor gefitinib. 
Similar to Cdk5 inhibition, gefitinib in combination 
with sorafenib reduced HCC cell proliferation and 
migration (Fig. 5D,E). Further, the analysis of a human 
HCC tissue micro array revealed overall increased 
EGFR protein levels in HCC tissue compared with 
healthy liver tissue (Supporting Fig. 7A-D). However, 
likely due to the small size and heterogeneity of the 
patient cohort, there was no correlation of EGFR 
positive staining, intensity, and immunoreactive score 
with tumor grading, r-classification, tumor stage, fre-
quency of recurrence, and cause of death (Supporting 
Table S1).
Collectively, this set of findings confirmed the 
compensatory activation of growth factor receptor 
pathways upon sorafenib treatment as a mechanism 
of HCC cells to sustain proliferative and migratory 
capacities and evade sorafenib treatment. Importantly, 
Cdk5 inhibition prevented the activation of the 
EGFR signaling cascade, despite not targeting the 
kinase activity of EGFR directly, suggesting a mode 
of action different from the classical inhibitors of 
growth factor receptors.
FIg. 2. Cdk5 inhibition prevents sorafenib-induced HCC cell migration. (A-E) Transwell migration of nt and Cdk5 shRNA HUH7 
(A,B), wild-type HUH7 cells (C), wild-type Hep3B cells (D) and nt and Cdk5 shRNA Hep3B cells (E) that were pretreated with the 
respective compounds in the indicated concentrations is shown. (F) Invasion of nt and Cdk5 shRNA HUH7 cells that were pretreated 
with sorafenib is shown. (A-F) Bar graphs indicate the number of migrated cells normalized to control. One-way analysis of variance 
(ANOVA), Tukey *P < 0.05, **P < 0.01, ***P < 0.001, n = 3. (G) Noninvasive images of tumor bearing mice injected with either RIL175 
wild-type cells or RIL175 Cdk5 knockout cells are shown. The bar graph shows corresponding signal intensities. t test, *P < 0.05, 
n = 10. (H) Noninvasive images of tumor-bearing mice treated with either Dinaciclib or solvent are shown. The bar graph shows 
corresponding signal intensities. t test, *P < 0.05, n = 10. Abbreviations: Cdk5 KO, Cdk5 knockout; WT, wild-type.
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Cdk5 IS eSSeNtIal For 
INtraCellUlar VeSICle 
traFFICKINg
So far, our results demonstrated that Cdk5 inhi-
bition interfered with the sorafenib-induced compen-
satory activation of the EGFR. Moreover, our results 
indicated a mechanism different from the classical 
receptor tyrosine kinase inhibitors. Because the pro-
teomic screen suggested that Cdk5 interfered with 
intracellular trafficking, in order to elucidate how 
Cdk5 perturbation interfered with EGFR activation, 
we focused on endocytosis of the receptor, which is 
crucial for EGFR signaling. After activation and 
dimerization, the EGFR is internalized and trafficked 
through early and late endosomes before the signal-
ing is either terminated by degradation via lysosomes 
or maintained by recycling via endosomes.(18) Cdk5 
inhibition had no effect on the uptake of the EGF/
EGFR complex (Fig. 6A). Conversely, it signifi-
cantly delayed the clearance of internalized EGFR 
(Fig. 6B), suggesting that a late step of EGFR traf-
ficking was affected. Consistently, we observed that 
upon the ablation of Cdk5, EGFR was perinuclearly 
enriched in aberrantly enlarged vesicle-like structures 
(Fig. 6C). To gain detailed insights into how Cdk5 
inhibition influences endosomal trafficking of EGFR, 
we performed live cell imaging using nt and Cdk5 
shRNA HUH7 and Hep3B cells overexpressing 
eGFP-tagged EGFR. Analysis of vesicle dynamics 
and size indicated, indeed, that vesicle trafficking was 
disturbed by Cdk5 inhibition. Control shRNA cells 
were characterized by small EGFR-positive vesicles 
moving with high velocity and distinct directionality. 
Cdk5 shRNA cells, instead, had large ring-shaped ves-
icles that showed impaired motility and accumulated 
in the perinuclear region (Fig. 6D; Supporting Video 
1 and 2). Importantly, this effect was not limited to 
the EGFR as Cdk5 knockdown similarly affected 
the size and motility of vesicles carrying integrin α5, 
a model protein for endocytic trafficking, and c-Met, 
the receptor for hepatocyte growth factor (Fig. 6E; 
Supporting Video 3-6). Especially the c-Met receptor 
is of particular interest in this context as it represents 
one of the most prominent and frequently deregulated 
growth factor receptors in HCC,(19,20) indicating that 
several important receptors can be targeted by Cdk5 
inhibition. These findings are in line with our obser-
vations of Cdk5 inhibition on the autophagic cascade, 
as autophagy is strongly interconnected with endo-
cytic trafficking.
In summary, our results demonstrated that Cdk5 
inhibition affects intracellular trafficking, as shown 
by the effects on endocytosis and autophagy, lead-
ing to the intracellular accumulation of various car-
gos that likely affect the extent and quality of signal 
activation. As a consequence, Cdk5 inhibition offers 
a global strategy to block the compensatory activa-
tion of growth factor receptors usually observed upon 
sorafenib. An overview about the findings of our study 
is given in Fig. 7.
Discussion
In 2008, the approval of the multi-tyrosine kinase 
inhibitor sorafenib fundamentally changed the treat-
ment of patients with advanced-stage HCC. The first 
approved systemic treatment increased both median 
overall survival and time to radiologic progression by 
about 3 months. However, the success was limited 
due to poor response rates and severe side effects.(4) 
Since then, the efforts to improve sorafenib efficacy 
by combining it with conventional chemotherapeu-
tics like doxorubicin or mammalian target of rapa-
mycin (mTOR) inhibitors has remained unsuccessful 
(reviewed in(6)). Furthermore, clinical trials investi-
gating new therapeutics, among others sunitinib,(21) 
brivanib,(22) and linifanib(23) as HCC therapy options, 
failed to replace sorafenib as the first-line treatment. 
Recently, palbociclib, an inhibitor of Cdk4/6, showed 
encouraging preclinical results in HCC treatment 
FIg. 3. Proteomic analysis of Cdk5 knockdown cells. (A) Table of proteins showing alterations of protein abundance (P < 0.05; 
log2-fold change > 0.6) between nt and Cdk5 shRNA HUH7 cells together with their respective gene names, x-fold changes (nt 
shRNA HUH7 versus Cdk5 shRNA HUH7) and P Values. (B) Volcano Plot visualizing the protein hits given in table A. (C) Protein 
interaction map of protein hits given in table A created with string-db.org (protein–protein interaction enrichment P Value: 0.0016). 
Proteins involved in metabolic processes, autophagy, and EGFR signaling are highlighted in red (false discovery rate: 0.0125). (D) The 
graph shows proteins associated with or regulated by endocytosis that were modulated by Cdk5 knockdown (x-fold change compared 
with nt shRNA is displayed).
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FIg. 4. Cdk5 inhibition inf luences autophagic f lux. (A) Immunoblots from nt and Cdk5 shRNA HUH7 cells treated with sorafenib 
probed with antibodies for p62/Sequestosome1 and LC3 are shown. (B) Quantitative evaluation of p62/Sequestosome1 from A is 
shown. One-way analysis of variance (ANOVA), Holm-Sidak *P < 0.05, n = 3. (C) Ratio of LC3-II to LC3-I after quantitative 
evaluation from A is shown. One-way ANOVA, Holm-Sidak *P < 0.05, n = 3. (D) LysoTracker Red staining of nt and Cdk5 shRNA 
HUH7 cells after treatment with concanamycin A (1 µM) is shown. (E) Immunoblot from nt and Cdk5 shRNA HUH7 cells treated 
with concanamycin A (1 µM) and probed with an antibody for LC3 is shown. (F) Ratio of LC3-II/I is shown after quantitative 
evaluation of immunoblots from E. One-way ANOVA, Newman-Keuls *P < 0.05, **P < 0.01, n = 3. (G) Single frames from live cell 
imaging videos of nt and Cdk5 shRNA HUH7 cells expressing eGFP-eRFP-LC3. Scale bar 10 µm (1×).
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alone or in combination with sorafenib.(24) By inhibit-
ing cell cycle progression, palbociclib suppressed HCC 
progression in vitro and in vivo. As a loss of RB1 led 
to acquired resistance to palbociclib, treatment with 
palbociclib is suggested for patients with intact RB1. 
In addition, two new, promising multi-tyrosine kinase 
inhibitors, regorafenib(7) and cabozantinib,(8) came 
into prospect as second-line treatment options for 
patients with HCC and achieved encouraging results 
in clinical trials (reviewed in(25)). Along these lines, 
regorafenib was recently approved for the treatment 
of patients with advanced HCC progressing under 
sorafenib treatment, and cabozantinib is expected to 
be approved as a second-line treatment in the foresee-
able future. Further, lenvatinib, a multi-tyrosine kinase 
inhibitor already used in the treatment of thyroid can-
cer, was shown to be noninferior to sorafenib in HCC 
treatment and is therefore considered for first-line 
HCC therapy approval.(9) However, sorafenib is thus 
far still the only first-line treatment; therefore, it is of 
paramount importance to search for ways to improve 
the impact of sorafenib on HCC.(25)
Here, we propose Cdk5 inhibition as a promis-
ing combination approach to increase the efficacy of 
sorafenib in HCC. Our results provide direct evidence 
that Cdk5 inhibition improves sorafenib treatment 
by interfering with the compensatory activation of 
growth factor receptors. Activation of parallel path-
ways to avoid chemotherapeutic treatment is com-
monly observed in cancer.(26) In HCC, in particular, 
activation of the Ras/Raf/MEK/ERK pathway, the 
PI3K/AKT/mTOR pathway, histone deacetylases 
(HDACs),(27) and growth factor receptors account for 
escape from sorafenib treatment. Thus, during recent 
years, the effects of combinations of sorafenib with 
inhibition of these pathways have been evaluated. 
The Ras/Raf/MEK/ERK pathway is often activated 
by Ras mutations. Accordingly, the combination of 
sorafenib with MEK inhibitors has shown some effi-
cacy in preclinical and clinical studies, especially if 
Ras was mutated.(28) In addition, elevated MAPK14 
was associated with poor response to sorafenib, and 
inhibition of MAPK14 was demonstrated to sensi-
tize for sorafenib treatment.(29) Activation of PI3K/
AKT/mTOR signaling can render HCC less sensi-
tive to sorafenib, and the combination of sorafenib 
and PI3K/AKT/mTOR inhibitors has shown 
encouraging results in a phase 1/2 study.(30) However, 
other studies reported severe side effects and failure 
to improve overall survival.(31,32) HDAC inhibitors 
in combination with sorafenib have shown promising 
results in preclinical studies, but subsequent clini-
cal trials had to be terminated due to severe toxic-
ity (reviewed in(33)). Altogether, although there have 
been various approaches to improve the clinical effect 
of sorafenib, most of them failed to show significant 
clinical efficacy.(34)
Growth factor receptor pathways are characterized 
by high redundancy and are therefore able to over-
come the malfunction of a pathway by over-activating 
another, leading to treatment evasion and tumor pro-
gression, which is often observed in HCC.(35) Studies 
showing increased metastasis upon sorafenib treat-
ment(36,37) are in line with our results that demon-
strate increased HCC cell migration and EGFR 
activation by sorafenib. However, up to now, there 
exist no detailed studies investigating a potential 
correlation between EGFR activation and sorafenib 
response in patients. Although EGFR is not an estab-
lished target in HCC therapy, our results, which show 
high levels of EGFR in human HCC, are in line with 
previous studies that demonstrated frequent overex-
pression of the EGFR in human HCC. The altered 
EGFR protein levels correlated with metastasis, 
FIg. 5. Cdk5 inhibition prevents compensatory activation of EGFR. (A) Immunoblots from nt and Cdk5 shRNA HUH7 cells 
treated with sorafenib probed with antibodies for pEGFR, EGFR, pErk, Erk, pAkt, and Akt are shown. (B) Quantitative evaluations 
of pEGFR, pErk and pAkt from A are shown. One-way analysis of variance (ANOVA), Tukey *P < 0.05, ****P < 0.0001, n = 3. (C) 
Immunostaining for EGFR with an antibody specific to the extracellular domain in nt and Cdk5 shRNA HUH7 (upper panel) and 
Hep3B (lower panel) cells after sorafenib treatment is shown. Scale bar 20 µm. Relative evaluation of f luorescence intensity is shown. 
One-way ANOVA, Tukey *P < 0.05, **P < 0.01, ***P < 0.001, n = 3. (D) Proliferation of HUH7 cells treated with sorafenib, gefitinib, 
or combination of both is shown. Corresponding doubling time is shown. One-way ANOVA, Tukey *P < 0.05, n = 3. Left panel: 
One representative graph (out of three independent experiments) shows the cell index over time. Right panel: Bar diagram shows the 
statistical analysis of cell index expressed as doubling time. (E) Transwell migration of wild-type HUH7 cells that were pretreated 
with the respective compounds in the indicated concentrations is shown. Representative pictures of migrated cells are shown together 
with bar diagrams showing the number of migrated cells normalized to the control. One-way ANOVA, Tukey ***P < 0.001, n = 3. 
Abbreviations: pAKT, phosphorylated AKT; pEGFR, phosphorylated EGFR; pErk, phosphorylated Erk.
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tumor aggressiveness, and poor patient survival.(14,38) 
However, a clinical benefit of the combination of 
EGFR inhibition with sorafenib has not been shown. 
According to the SEARCH trial, the combination of 
sorafenib with the EGFR inhibitor erlotinib failed to 
improve survival in patients with HCC.(39) In sum-
mary, sorafenib combination therapies have shown 
some benefits, but exhibited severe toxicity and failed 
to improve overall survival. Thus, there is still no 
sorafenib combination approach that is clinically used 
in HCC therapy.
Importantly, our results reveal a mode of action of 
Cdk5 in HCC to interfere with growth factor receptor 
activation, different from the classical receptor tyro-
sine kinase inhibitors. By interfering with intracellular 
receptor trafficking, Cdk5 inhibition—in contrast to 
FIg. 7. Summary. (A) The treatment of HCC cells with sorafenib causes an inhibition of VEGFR and its downstream targets 
RAS and RAF. (B) In turn, this leads to the compensatory activation of growth factor receptor signaling, which allows tumor cells 
to maintain proliferation and migration, mediated via the PI3K/AKT pathway. After activation, growth factor receptors have to be 
trafficked via the endosomal system and are either degraded via lysosomes or recycled via endosomes. (C) We uncovered that Cdk5 
inhibition interferes with intracellular trafficking leading to an increase in vesicle size and an accumulation of respective cargos. (D) 
Thereby an inhibition of Cdk5 prevents the sorafenib-induced compensatory activation of growth factor receptors and respective 
downstream targets and enhances the antitumor effects of sorafenib.
FIg. 6. Cdk5 influences endosomal trafficking. (A) EGF-uptake: Images display nt and Cdk5 shRNA HUH7 cells that were treated 
with EGF-Rhodamine for various time points and analyzed by confocal microscopy. Scale bar 25 µm. Quantitative evaluation of 
CTCF is shown. For each condition, 30 cells were analyzed. (B) EGF-elimination: Images show nt and Cdk5 shRNA HUH7 cells 
that were incubated with EGF-Rhodamine (30 minutes) before EGF-Rhodamine was removed and cells were chased for the given 
time points (0, 5, 30, and 60 minutes). Scale bar 25 µm. Quantitative evaluation of CTCF is indicated. One-way analysis of variance, 
Tukey *P < 0.05, **P < 0.01, n = 3. (C) Immunostaining for EGFR (green), EEA1 (red), and Hoechst33342 (blue, nuclei) from nt and 
Cdk5 shRNA HUH7 cells is shown. Scale bar 25 µm. (D) Single frames from live cell imaging videos of nt and Cdk5 shRNA cells 
expressing eGFP-EGFR are shown. Scale bar 10 µm. Box plot diagram and bar graph show the distribution of vesicle size comparing 
nt and Cdk5 shRNA. Mann-Whitney, ****P < 0.0001, chi-squared test, ****P < 0.0001. (E) Single frames from live cell imaging videos 
of nt and Cdk5 shRNA HUH7 and Hep3B cells expressing either eGFP-Integrin-α5, eGFP-cMet, or eGFP-EGFR are shown. Scale 
bar 25 µm (HUH7: integrin α5), 10 µm (HUH7: c-Met, EGFR; Hep3B: integrin α5, EGFR, c-Met). Abbreviation: CTCF, corrected 
total cell f luorescence.
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the unsuccessful inhibition of only EGFR by erlo-
tinib—offers a global approach to block the compen-
satory activation of growth factor receptors. Thus, our 
study suggests Cdk5 inhibition as a potential option 
to improve sorafenib efficacy.
Like many growth factor receptor pathways, the 
EGFR pathway critically depends on endosomal traf-
ficking to uphold or terminate the signaling.(18) We 
showed that Cdk5 inhibition disturbs endosomal traf-
ficking, which leads to an accumulation of respective 
cargo and an enlargement of endosomal vesicles, thereby 
inhibiting receptor activity. In the context of cancer, an 
involvement of Cdk5 in endocytic trafficking has not 
been described yet; however, there is evidence that 
Cdk5 plays an important role in regulating endocytosis 
in the neuronal system. In neurons, a role of Cdk5 in 
intracellular trafficking has been established.(40) Cdk5 
drives synaptic vesicle endocytosis by phosphorylating 
the dephosphins dynamin I, amphiphysin, and synap-
tojanin and regulates endocytosis of the N-methyl-D-
aspartate receptor at postsynaptic sites (reviewed in(41)). 
Moreover, during axon outgrowth, Cdk5 was shown to 
regulate Rab proteins, which coordinate vesicle traffick-
ing, fusion, and maturation.(42)
During recent years, endocytosis has emerged as 
a central process in cancer. Endocytic circuitries are 
deeply interconnected with the activation and execu-
tion of various pathways that regulate cancer growth, 
progression, and metastasis, including small GTPases, 
integrin, epithelial-mesenchymal transition, and 
growth factor receptor signaling.(43) Thus, strategies 
to interfere with endocytosis have shown promis-
ing anticancer effects.(44-46) Within this context, our 
results define Cdk5 as a central regulator of endocytic 
processes in cancer.
Along this line, our results show that Cdk5 inhibi-
tion influences and disturbs autophagic flux, an intra-
cellular trafficking pathway highly interconnected 
with endocytosis. Autophagy has been associated 
with cancer progression and was recently shown to be 
involved in the development of resistance to sorafenib 
in HCC (reviewed in(47)). This underlines the global 
effect of Cdk5 inhibition on intracellular trafficking 
and establishes the possibility to target two separate 
mechanisms of resistance to sorafenib in HCC, auto-
phagy and endocytosis.
Of note, as Cdk5 represents a clinically relevant 
target, Cdk5 inhibition is indicated as a promising 
option to prevent the compensatory activation of 
growth factor receptors. Cdk5 can be pharmacolog-
ically targeted by Dinaciclib, a small molecule Cdk5 
inhibitor that has shown promising anticancer effects 
with a manageable side-effect profile in clinical trials. 
Dinaciclib is a well-tolerated compound and has been 
successfully evaluated as therapy of chronic lympho-
cytic leukemia in phase III clinical trials and is cur-
rently under clinical investigation for the treatment of 
other types of leukemia.(48,49) According to our study, 
Dinaciclib represents a promising therapeutic option 
for HCC that increases sorafenib efficiency and 
inhibits treatment escape.
In conclusion, our study presents Cdk5 inhibition 
as a promising approach to increase sorafenib effi-
cacy in HCC that might contribute to improve the 
therapeutic situation for patients with advanced-stage 
HCC.
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